Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside

Author： Vincenzi Bruno   Napolitano Andrea   D'Onofrio Loretta   Frezza Anna Maria   Silletta Marianna   Venditti Olga   Santini Daniele   Tonini Giuseppe  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.12, 2011-12, pp. : 1685-1705

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside

By  

Current Medicinal Chemistry, Vol. 14, Iss. 19, 2007-08 ,pp. : 2009-2023

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the mammalian target of rapamycin

By Dancey Janet E  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 3, 2005-03 ,pp. : 313-328

Informa Healthcare

Access to resources Recommend Favorite

MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside

By  

Current Medicinal Chemistry, Vol. 21, Iss. 8, 2014-01 ,pp. : 975-989

Bentham Science Publishers

Access to resources Recommend Favorite

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer

By Nelson Valerie   Altman Jessica K   Platanias Leonidas C  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 715-722

Informa Healthcare

Access to resources Recommend Favorite

Current and future directions in mammalian target of rapamycin inhibitors development

By Fasolo Angelica   Sessa Cristiana  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 3, 2011-03 ,pp. : 381-394

Informa Healthcare

Access to resources Recommend Favorite